Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics.

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY

Journal of Clinical Neurology Pub Date : 2025-05-01 DOI:10.3988/jcn.2024.0550

Sung Hoon Kang, Jee Hyang Jeong, Jung-Min Pyun, Geon Ha Kim, Young Ho Park, YongSoo Shim, Seong-Ho Koh, Chi-Hun Kim, Young Chul Youn, Dong Won Yang, Hyuk-Je Lee, Han Lee, Dain Kim, Kyunghwa Sun, So Young Moon, Kee Hyung Park, Seong Hye Choi

{"title":"Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics.","authors":"Sung Hoon Kang, Jee Hyang Jeong, Jung-Min Pyun, Geon Ha Kim, Young Ho Park, YongSoo Shim, Seong-Ho Koh, Chi-Hun Kim, Young Chul Youn, Dong Won Yang, Hyuk-Je Lee, Han Lee, Dain Kim, Kyunghwa Sun, So Young Moon, Kee Hyung Park, Seong Hye Choi","doi":"10.3988/jcn.2024.0550","DOIUrl":null,"url":null,"abstract":"Background and purpose: We aimed to determine the proportion of Korean patients with early Alzheimer's disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment.Methods: We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study.Results: When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22.Conclusions: Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 3","pages":"182-189"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056135/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3988/jcn.2024.0550","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose: We aimed to determine the proportion of Korean patients with early Alzheimer's disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment.

Methods: We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study.

Results: When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22.

Conclusions: Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.

查看原文本刊更多论文

韩国莱卡耐单抗治疗的资格：来自记忆诊所的真实世界数据

背景和目的：我们旨在确定韩国早期阿尔茨海默病（AD）患者根据美国适当使用建议（US AUR）有资格接受莱卡耐单抗治疗的比例，并确定这种治疗的障碍。方法：从2023年6月至2024年5月，我们回顾性地纳入了13家医院的6132例患有遗忘性轻度认知障碍或轻度遗忘性痴呆的患者。其中，2058例患者行淀粉样正电子发射断层扫描（PET），其中1199例（58.3%）为淀粉样蛋白阳性。我们排除了732名在2023年6月至2024年5月期间未接受脑磁共振成像的患者。最终，467例患者被纳入本研究。结果：当应用美国AUR标准时，大约50%的早期AD患者有资格接受莱卡耐单抗治疗。在纳入的467例患者中，36.8%的患者不符合简易精神状态检查（MMSE）得分≥22的纳入标准。结论：除了MMSE评分≥22的患者外，莱卡耐单抗治疗的资格并不局限于韩国早期AD患者。因此，应该在老年人比例较高的地区重新考虑MMSE标准，老年人往往受教育程度较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Neurology 医学-临床神经学

CiteScore

4.50

自引率

6.50%

发文量

审稿时长

>12 weeks

期刊介绍： The JCN aims to publish the cutting-edge research from around the world. The JCN covers clinical and translational research for physicians and researchers in the field of neurology. Encompassing the entire neurological diseases, our main focus is on the common disorders including stroke, epilepsy, Parkinson''s disease, dementia, multiple sclerosis, headache, and peripheral neuropathy. Any authors affiliated with an accredited biomedical institution may submit manuscripts of original articles, review articles, and letters to the editor. The JCN will allow clinical neurologists to enrich their knowledge of patient management, education, and clinical or experimental research, and hence their professionalism.